Your browser doesn't support javascript.
loading
Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.
Scally, Stephen W; Murugan, Rajagopal; Bosch, Alexandre; Triller, Gianna; Costa, Giulia; Mordmüller, Benjamin; Kremsner, Peter G; Sim, B Kim Lee; Hoffman, Stephen L; Levashina, Elena A; Wardemann, Hedda; Julien, Jean-Philippe.
  • Scally SW; Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
  • Murugan R; B Cell Immunology, German Cancer Research Center, Heidelberg, Germany.
  • Bosch A; Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
  • Triller G; B Cell Immunology, German Cancer Research Center, Heidelberg, Germany.
  • Costa G; Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
  • Mordmüller B; Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen, Tübingen, Germany.
  • Kremsner PG; Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen, Tübingen, Germany.
  • Sim BKL; Sanaria Inc., Rockville, MD.
  • Hoffman SL; Sanaria Inc., Rockville, MD.
  • Levashina EA; Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
  • Wardemann H; B Cell Immunology, German Cancer Research Center, Heidelberg, Germany h.wardemann@dkfz.de.
  • Julien JP; Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada jean-philippe.julien@sickkids.ca.
J Exp Med ; 215(1): 63-75, 2018 01 02.
Article en En | MEDLINE | ID: mdl-29167197
ABSTRACT
Antibodies against the central repeat of the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) inhibit parasite activity and correlate with protection from malaria. However, the humoral response to the PfCSP C terminus (C-PfCSP) is less well characterized. Here, we describe B cell responses to C-PfCSP from European donors who underwent immunization with live Pf sporozoites (PfSPZ Challenge) under chloroquine prophylaxis (PfSPZ-CVac), and were protected against controlled human malaria infection. Out of 215 PfCSP-reactive monoclonal antibodies, only two unique antibodies were specific for C-PfCSP, highlighting the rare occurrence of C-PfCSP-reactive B cells in PfSPZ-CVac-induced protective immunity. These two antibodies showed poor sporozoite binding and weak inhibition of parasite traversal and development, and did not protect mice from infection with PfCSP transgenic Plasmodium berghei sporozoites. Structural analyses demonstrated that one antibody interacts with a polymorphic region overlapping two T cell epitopes, suggesting that variability in C-PfCSP may benefit parasite escape from humoral and cellular immunity. Our data identify important features underlying C-PfCSP shortcomings as a vaccine target.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Plasmodium falciparum / Anticuerpos Antiprotozoarios / Proteínas Protozoarias / Malaria Falciparum / Vacunas contra la Malaria Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Plasmodium falciparum / Anticuerpos Antiprotozoarios / Proteínas Protozoarias / Malaria Falciparum / Vacunas contra la Malaria Idioma: En Año: 2018 Tipo del documento: Article